Systemic lupus erythematosus and ANCA-associated vasculitis overlap syndrome: A case report and literature review of poliautoimmunity

Ana Gaspar¹, Anna Lima¹, Afonso Santos¹, Catarina Brás¹, Rita Theias Manso², Karina Soto¹

¹ Nephrology Department, Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal
² Pathology Department, Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal

ABSTRACT

Systemic lupus erythematosus and ANCA-associated vasculitis (AAV) are traditionally considered to be two distinct conditions that explain the interaction between these two conditions are still unclear. The authors describe the case of a patient who had myeloperoxidase ANCA-associated vasculitis as the initial diagnosis, with biopsy-proven pauci-immune crescentic glomerulonephritis, attaining complete remission after immunosuppression. Five years later, Systemic Lupus Erythematosus was diagnosed and a second kidney biopsy showed a pattern of lupus nephritis class III. While on immunosuppression treatment, the patient developed a progressive elevation of liver enzymes and was later diagnosed with primary biliary cholangitis. It seems that in this case, the overlap of Systemic Lupus Erythematosus and ANCA-associated vasculitis may be part of a poliautoimmune syndrome suggested by association with a third autoimmune disease.

Keywords: ANCA-associated vasculitis; Primary biliary cholangitis; Systemic Lupus Erythematosus

INTRODUCTION

Systemic lupus erythematosus (SLE) and ANCA-associated vasculitis (AAV) are traditionally considered to be two distinct conditions that affect the kidney structurally and functionally through different mechanisms.

SLE is characterized by the presence of serum autoantibodies against nuclear components such as antinuclear antibodies (ANA), extractable nuclear antigens (ENA) antibodies, which include RNP and Smith antigens, and double strand DNA (dsDNA) antibodies. It has a heterogeneous clinical presentation, displaying a wide spectrum of manifestations including lupus nephritis (LN) in 30-60% of cases and vasculitis in 11% of patients. SLE leads to an immune complex glomerulonephritis. The patterns of glomerulonephritis seen in LN have been classified by the 2004 International Society of Nephrology (ISN) /Renal Pathology Society (RPS) classification (GN).

On the other hand, AAV is a small vessel systemic vasculitis caused by serum autoantibodies against polymorphonuclear leukocytes, most commonly anti-neutrophil cytoplasmic antibodies (ANCA) anti-myeloperoxidase (MPO) or anti-proteinase 3 (PR3) and is expressed in the kidney as pauci-immune crescentic glomerulonephritis. Vasculitis may occur in patients with SLE, but rarely meets the criteria for AAV.

The SLE/AAV overlap syndrome (SLE/AAV OS) was first described in 2008 for patients who met criteria for both conditions. It seems that a possible shared immune pathogenesis may exist, but the exact mechanism is unclear and that the overlap of SLE and AAV may be part of a poliautoimmune syndrome suggested by association with a third autoimmune disease.

CASE REPORT

A 47-year-old African-descent woman with an unremarkable past medical history presented with nephritic syndrome and severe rapidly progressive renal failure requiring renal replacement treatment (RRT). She complained of asthenia and significant weight loss over the previous 6 months.

The laboratory tests showed a serum creatinine (sCr) of 8.2 mg/dL, microscopic hematuria and proteinuria of 3.9g/day. The immunological workup identified MPO-ANCA (6.63 UI/mL), ANA (titer >1/640) and nRNP/Smith antibodies. Other specific antibodies were absent. SLE leads to an immune complex glomerulonephritis. The patterns of glomerulonephritis seen in LN have been classified by the 2004 International Society of Nephrology (ISN) /Renal Pathology Society (RPS) classification (GN).

On the other hand, AAV is a small vessel systemic vasculitis caused by serum autoantibodies against polymorphonuclear leukocytes, most commonly anti-neutrophil cytoplasmic antibodies (ANCA) anti-myeloperoxidase (MPO) or anti-proteinase 3 (PR3) and is expressed in the kidney as pauci-immune crescentic glomerulonephritis. Vasculitis may occur in patients with SLE, but rarely meets the criteria for AAV.

The SLE/AAV overlap syndrome was first described in 2008 for patients who met criteria for both conditions. It seems that a possible shared immune pathogenesis may exist, but the exact mechanism is unclear and that the overlap of SLE and AAV may be part of a poliautoimmune syndrome suggested by association with a third autoimmune disease.

Keywords: ANCA-associated vasculitis; Primary biliary cholangitis; Systemic Lupus Erythematosus

Received for publication: Jan 17, 2021 • Accepted in revised form: Mar 8, 2021 • http://doi.org/10.32932/pjn.2021.04.118
a favorable response after the first CyP cycle, with improvement of kidney function and RRT suspension. Complete remission was achieved after the third month of treatment. She received an additional 2 months of IV CyP but due to an increase of liver enzymes, CyP was withdrawn, and maintenance treatment with azathioprine (AZA) (50mg q.d.) and prednisolone was started. However, after four months, AZA was also withdrawn for the same reason. Other causes for the elevation of the liver enzymes, such as hepatotropic viruses, were excluded and liver ultrasound showed no alterations. Prednisolone was tapered over 6 months, completing a total of 15 months. She maintained complete AAV remission through long-term outpatient nephrology follow-up, but ANA antibodies remained positive.

Five years later she presented with non-nephrotic proteinuria (2g/day), microscopic hematuria and tenderness and morning stiffness on several joints. A new immunological workup showed persistency of ANA (>1/640) and nRNP/Smith antibodies and de novo dsDNA (54UI/ml), sp100 and gp210 antibodies. Complement factor C3 levels were decreased and C4 levels were within normal range. ANCA antibodies were negative. Given these findings, she was diagnosed with SLE and initially treated with hydroxychloroquine (HCQ) and angiotensin converter enzyme inhibitor (ACEI) for 10 months. However there was an increase of proteinuria with persistency of all serum antibodies and a new kidney biopsy was performed.

The second kidney biopsy showed a diffuse mesangioproliferative GN (Figure 2A), with sclerotic lesions in 64% of glomeruli on light microscopy. There was no significant interstitial inflammation, interstitial fibrosis or tubular atrophy. Immunofluorescence (Figure 2B) showed small IgG granular deposits in the mesangium and in the
capillary wall. Staining for IgA, IgM, C3, C4 and C1q was negative. EM showed focal endocapillary proliferation and amorphous electron dense deposits in the sub-endothelial compartment (Figure 2C) and in the mesangium. There was also persistency of tubuloreticular inclusions. Given the clinical context, these findings were consistent with lupus nephritis class III with a NIH activity index of 1/24 and chronicity index of 3/12. She started treatment with pulsed methylprednisolone (250mg) for 3 days, followed by prednisolone and mycophenolate mofetil (MMF) (500mg b.i.d.). However, a progressive increase of liver enzymes determined the withdrawal of MMF after 3 months. She maintained treatment with HQC, ACEI and prednisolone, which was tapered and discontinued after 12 months, with progressive improvement of kidney function and proteinuria and partial serologic remission, with ANA persistency.

Given the recurrent elevation of transaminases, alkaline phosphatase and gamma-glutamyl transferase and the presence of anti-Sp100 and anti-gp210 antibodies along with ANA, she was later diagnosed with primary biliary cholangitis (PBC), and was later started on ursodeoxycholic acid. Liver elastography showed mild to moderate liver fibrosis (F1-F2).

**DISCUSSION**

This case report describes a challenging diagnosis of SLE/AAV OS as part of poliautoimmunity syndrome, as it was associated with the diagnosis of a third autoimmune disease during the long-term follow-up of the patient.

SLE/AAV overlap syndrome (SLE/AAV OS) was first described in 2008 by Nasr and colleagues for patients who met criteria for both conditions. The prevalence of SLE/AAV OS is low, representing about 2% in patients with GN as published in a 2016 French national survey. Most of the patients are female, with a mean age around the second decade, showing severe clinical features at presentation such as pauci-immune necrotizing GN and pulmonary hemorrhage. AAV and SLE can develop concurrently or several years apart and features like the presence of ANA and tubuloreticular inclusions at the time of AAV diagnosis such as in the present case are common. The vast majority of cases reported are MPO-ANCA.

There is some evidence in the literature of an association between SLE and AAV. SLE and AAV share some immunological features and can probably be triggered by the same stimuli. Also, some authors suggest that crescentic necrotizing pauci-immune GN may represent a rare variation of LN, in which ANCA is the driving factor via neutrophil activation, cytokine release and endothelial damage, resulting in necrosis and crescent formation. On the other hand, ANCA antibodies frequently occur in SLE patients (16-20%) but many these bodies and low C3 levels).

Regarding the SLE diagnosis 5 years later, she scored 25 points on the new 2019 EULAR/ACR criteria for a minimum of 10 points for SLE diagnosis. These included the presence of ANA antibodies and joint involvement with tenderness and morning stiffness on more than two joints (6 points); presence of dsDNA and Smith antibodies (6 points); decreased C3 serum levels (3 points), and biopsy-proven class III Lupus Nephritis (10 points). She also scored 5 criteria on the 2012 Systemic Lupus Collaborating Clinics (SLICC) criteria for a minimum of 4 for SLE diagnosis, one of them being a clinical criterion with biopsy proven class III Lupus Nephritis (2004 International Society of Nephrology (ISN) /Renal Pathology Society (RPS) classification) and the remaining, immunological criteria (presence of ANA, dsDNA and anti-Smith antibodies and low C3 levels).

The clinical presentation, serological pattern and kidney biopsy findings determined the start of immunosuppressive treatment, with a positive response. The integration of light microscopy, IF and EM, allowed a more accurate diagnosis on the second biopsy. Although IF had been scarce, the presence of mesangial and sub-endothelial deposits, the tubuloreticular inclusions and overall clinical context supported LN and SLE diagnosis.

Adding to the complexity of this case was that the patient was diagnosed with PCB. The association of this condition with SLE or AAV is rare and, to the best of our knowledge, the association with SLE/AAV OS has not been previously described in the literature. One review regarding SLE and PCB in 34 case reports concluded that most of these patients were female, and PCB was usually diagnosed before SLE, with SLE being late onset. Another review, published in 2019, showed that the association of AAV with other autoimmune disorders is rare; only 3 out of 28 patients with AAV associated to another autoimmune condition presented with AAV and PCB simultaneously. According to some authors, SLE and AAV could be part of a complex poliautoimmune syndrome, in which SLE/AAV OS can be associated with a third autoimmune disease, such as the present case. Tissue damage during an immune response can lead to the priming of self-reactive T and/or B lymphocytes, despite the initial insult. The shift and diversification of autoantibody targets during the course of autoimmune diseases has been defined as epitope spreading and has been described in SLE, explaining the broad of autoantibodies that can be found in this disease and also the association with other autoimmune diseases. This phenomenon was also studied in patients with AAV and other autoantibodies or other autoimmune diseases.

Given the diagnosis of focal proliferative LN, this patient has a high risk for relapse and progression to chronic kidney disease and according to current guidelines she should receive maintenance treatment with a second immunosuppressive drug in addition to prednisolone, such as MMF or AZA. However, regarding the PCB diagnosis, the patient has mild to moderate liver fibrosis and serologic markers, such as ANA, anti-Sp100 and anti-gp210 that correlate with progression to chronic liver failure and cirrhosis. Also, it is likely that the immunosuppressive drugs contributed to the transitory elevation of liver enzymes...
on the various occasions. In a trial from 2005, the use of MMF on PCB patients was associated with a high percentage of adverse advents23. In the future, other therapeutic approaches for LN, such as rituximab24, should be considered.

Disclosure of potential conflicts of interest: none declared.

References


Correspondence to:
Ana Gaspar, MD
Nephrology Department
Hospital Prof. Doutor Fernando Fonseca
IC19, 2720-276 Amadora, Portugal
E-mail: ana.ccs.gaspar@gmail.com